新闻档案

通过选择所需的新闻类型,可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见,某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处,请以PDF版本为准。

新闻类型
演示文稿
监管信息公告
新闻主题
创新平台
商业平台
监管通知
集团
12
3
找到相关结果: 133
Australia Phase I study to report in late 2013 London: Tuesday, 25 June 2013:  Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated the Phase I clinical trial of Volitinib (HMPL-50
阅读更多
London: Wednesday, 31 October 2012: Chi-Med announced that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309).  This is the fourth oncology comp
阅读更多
London: Wednesday, 22 February 2012: Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Volitinib (HMPL-504) in Australia.  Volitinib
阅读更多
London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen
阅读更多
London, Friday, 4 November 2011: Hutchison MediPharma Limited (“HMP”), the drug R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Epitinib (HMPL-813).  This is the third onc
阅读更多
London: Tuesday, 1 February 2011: Hutchison MediPharma Limited (“Hutchison MediPharma”), the drug R&D company majority owned by Chi-Med, today announces that it has started the first-in-human Phase I clinical trial of its anti-cancer drug can
阅读更多
12
3